How we used to identify monoclonal proteins (electrophoresis, immunofixation, left).

How we identify monoclonal proteins now @MayoClinic (mass spectrometry, right).

#myeloma #MGUS #MedTwitter
Patient with IgA monoclonal protein with molecular weight of 23484.7 diagnosed in 2007.

Same patient had same monoclonal protein 10 years ago that was not detected by immunofixation, but we could readily detect on mass spec done on archival serum sample.
Mass spec is more accurate, easier and more efficient for labs. @moricemdphd
Using clinical grade mass spectrometry, we estimate 5% of the general population age 50 and older has a monoclonal protein, (MGUS).

Our prior estimate with electrophoresis and immunofixation was 3%. @BloodCancerJnl @MayoMyeloma nature.com/articles/s4140…
Mass spec needs expertise in set up and interpretation. If you don't know what you are doing, you can find a "monoclonal protein" in everyone.

So we have to set the right thresholds for proper clinical use.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Vincent Rajkumar

Vincent Rajkumar Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @VincentRK

Jul 20
Anyone who says Medicare negotiating for prescription drugs won't work has a financial conflict or interest or no idea what they are talking about.

1/
Every other developed country negotiates. That's why they pay much less for the same drugs as us.

2/
You cannot grant prolonged monopoly protection to Pharma, agree to buy and provide drugs for the public, and simultaneously pass a law that says you will pay up whatever Pharma wants without negotiation. That's not capitalism. Opposite of free market.

3/
Read 11 tweets
Jul 19
You can make CAR-T cells in one day if you wanted to. The technology is here. The current regulatory system will be the barrier. Not the science.

China will become the destination center. @NoopurRajeMD @DavidP4AD @kenderian_ss @Rfonsi1 @BloodCancerJnl nature.com/articles/s4140…
We wrote 2 years ago how regulatory reforms can help us realize the full potential of CAR-T cell therapy, and can also save us billions. @statnews statnews.com/2019/11/20/car…
The amazing potential of CAR-T is that we can tailor it to the exact antigens on the cell surface of the specific patients' cancer cell. Target it against two or more antigens to get the beat efficacy.
Read 7 tweets
Jul 13
Breaking: FDA authorizes Novovax. It's welcome news and I only wish it had happened sooner. #CovidVaccine nbcnews.com/health/health-…
Now we have to figure out how to best incorporate into the overall COVID vaccination strategy.

It's a whole different vaccine than Pfizer or Moderna. Protein-based vs mRNA. Beyond being an alternative it may offer something more.
*Novavax
Read 5 tweets
Jul 12
BA.5 is a threat. I spoke to @DrEricDing on new COVID variants, boosters, and retooled vaccines. @ConvSix @ambassadorbrief

BA.5 is surging and is much more evasive to prior immunity. Full 6 minutes here: conversationsix.com/p/7ATicfMXjimG…
We are not testing enough two we have no idea of the case load or extent of spread.

Waste water readings point to higher spread than we count. wsj.com/articles/hopes…
We are hoping for retooled vaccines that work against BA.4 and BA.5 by fall. The FDA has asked Pharma companies to modify the vaccines accordingly.

The ones that were promising against omicron BA.1 and BA.2 (see below) may not work against BA.5. That's how fast its evolving.
Read 5 tweets
Jul 11
Those interested in myeloma should know about the costs of treatment.
So when we choose a particular regimen or dose over the other, the cost difference is astronomical. We need good data to justify the cost difference.

For example look at cost difference between KRd at two dose levels.
Except for CAR-T which right now is a one time treatment, these are annual costs. Patients take these kind of treatments for years. It adds up.

Choosing the sequence wisely depending on access and affordability is critical.
Read 5 tweets
Jul 10
There are 335 million people in the US. Even if 0.1% are troubled, that's >200,000 who can crack under pressure. You cannot possibly know or track a fraction of them, let alone all.

Preventing mass shootings by trying to identify these people just in time is wishful thinking.
The proportion of people with mental illness is far higher than 0.1%. All countries have the same problem. But we stand alone in the number of mass shootings.

With 400 million guns it's too easy for troubled people to get one.
This is an important article with a lot of detailed data and graphics. @markberman @LennyMBernstein @abtran @arturgalocha @washingtonpost apple.news/A0L_zteKjSOe81…
Read 5 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(